Corporate Banner
Satellite Banner
Technology Networks Header
Friday, September 19, 2014
Technology Networks
 
Register | Sign in
Home Page
  Permissions

Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd

To obtain this permission contact:
Technology Networks Ltd
Unit 6, Woodview
Bull Lane
Acton
Sudbury
CO10 0FD, U.K.

In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved.

The information and data included in the TechnologyNetworks.com WWW site, and all its affiliated websites and associated email newsletters, have been compiled from a variety of sources, and are subject to change without notice. Technology Networks Ltd. makes no warranties or representations whatsoever regarding the quality, content, completeness, or adequacy of this information and data.

Technology Networks Ltd. specifically disclaims all warranties with respect to this WWW site, email newsletters or your use thereof, express, implied, or otherwise, including without limitation, all warranties of merchantability and fitness for a particular purpose. Technology Networks Ltd shall not be liable for any special, incidental, or consequential damages, including, without limitation, lost revenues, lost profits, or loss of prospective economic advantage, resulting from the use or misuse of this site, or the information therein.

Scientific News
Intestinal Bacteria Needed for Strong Flu Vaccine Responses in Mice
Study demonstrate a dependency on gut bacteria for strong immune responses to the seasonal flu and inactivated polio vaccines.
Novel Immunotherapy Breast Cancer Vaccine
Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients.
Cell ‘Memory’ Could be Key to Strengthen Vaccine Efficacy
Virginia Tech Carilion Research Institute scientists uncover immune system secret.
NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
The antibody, 35O22, prevents 62 percent of known HIV strains from infecting cells in the laboratory.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Understanding and Improving the Body's Fight Against Pathogens
A*STAR scientists find new targets for modulating antibody response.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
MU Researchers Discover Protein's Ability To Inhibit HIV Release
TIM-family proteins have the ability to block the release of HIV and other viruses.
High Capacity Antibody Purification
Researchers from the A*Star Bioprocessing Technology Institute have used magnetic nanoparticles to break the capacity barrier for antibody purification.
Experimental Chikungunya Vaccine Induces Robust Antibody Response
Vaccine developed by NIH scientists performs well in early clinical trial.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv